Ratings by Jefferies (Andrew Tsai)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/18/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | Alto Neuroscience | ANRO | New Coverage | Buy (N/A) |
13.72 (14.13) |
2.99% | Details | |
| 2/8/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2024 | Vertex | VRTX | Maintain | Hold (Hold) |
|
Details | ||
| 12/7/2023 | VistaGen Therapeutics | VTGN | Upgrade | Buy (Hold) |
4.29 (4.70) |
9.56% | Details | |
| 10/4/2023 | POINT Biopharma Global Inc. | PNT | Downgrade | Hold (Buy) |
6.68 (12.50) |
87.13% | Details | |
| 7/20/2023 | POINT Biopharma Global Inc. | PNT | New Coverage | Buy (N/A) |
9.24 (12.50) |
35.28% | Details | |
| 5/29/2023 | Annexon Biosciences | ANNX | Maintain | Buy (N/A) |
|
Details | ||
| 5/16/2023 | Savara | SVRA | New Coverage | Buy (N/A) |
1.99 (4.45) |
123.62% | Details | |
| 3/7/2023 | Lexicon Pharmaceuticals | LXRX | New Coverage | Hold (N/A) |
2.68 (1.54) |
-42.54% | Details | |
| 12/19/2022 | Vertex | VRTX | Downgrade | Hold (Buy) |
308.40 (397.70) |
28.96% | Details | |
| 11/9/2022 | Marinus Pharmaceuticals | MRNS | Maintain | Buy (N/A) |
|
Details | ||
| 7/22/2022 | VistaGen Therapeutics | VTGN | Downgrade | Hold (Buy) |
1.07 (4.70) |
339.25% | Details | |
| 7/6/2022 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2022 | Athira Pharma | ATHA | Downgrade | Hold (Buy) |
8.45 (1.92) |
-77.28% | Details | |
| 6/21/2022 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 5/31/2022 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2022 | atai Life Sciences N.V | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/1/2022 | Vigil Neuroscience Inc | VIGL | New Coverage | Buy (N/A) |
14.65 (2.58) |
-82.39% | Details | |
| 1/25/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 10/4/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 9/20/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 9/1/2021 | atai Life Sciences N.V | ATAI | New Coverage | Buy (N/A) |
15.93 (1.84) |
-88.45% | Details | |
| 8/30/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2021 | VistaGen Therapeutics | VTGN | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2021 | Minerva Neurosciences | NERV | New Coverage | Hold (N/A) |
2.41 (2.43) |
0.83% | Details | |
| 6/8/2021 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2021 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 4/16/2021 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2021 | Marinus Pharmaceuticals | MRNS | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2021 | VistaGen Therapeuticsen Therapeutics | VTGN | New Coverage | Buy (N/A) |
1.99 (4.70) |
136.18% | Details | |
| 12/21/2020 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 10/13/2020 | Athira Pharma | ATHA | New Coverage | Buy (N/A) |
16.81 (1.92) |
-88.58% | Details | |
| 9/15/2020 | Marinus Pharmaceuticals | MRNS | Maintain | Buy (N/A) |
|
Details | ||
| 5/31/2020 | Xenon Pharmaceuticals | XENE | New Coverage | Buy (N/A) |
12.70 (40.10) |
215.75% | Details | |
| 1/27/2020 | Relmada Therapeutics Inc | RLMD | New Coverage | Buy (N/A) |
40.66 (3.70) |
-90.9% | Details | |
| 9/16/2019 | Zynerba Pharmaceuticals | ZYNE | New Coverage | Hold (N/A) |
12.19 (1.30) |
-89.34% | Details | |
| 8/12/2019 | Intra-Cellular Therapies | ITCI | New Coverage | Buy (N/A) |
9.23 (72.13) |
681.47% | Details | |
| 7/23/2019 | Marinus Pharmaceuticals | MRNS | Maintain | Buy (N/A) |
|
Details | ||
| 4/25/2019 | Sage Therapeutics | SAGE | New Coverage | Buy (N/A) |
166.98 (13.58) |
-91.87% | Details | |
| 3/5/2019 | Marinus Pharmaceuticals | MRNS | New Coverage | Buy (N/A) |
3.49 (1.42) |
-59.31% | Details |
